A new cyclooxygenase-2 inhibitor, rofecoxib (VIOXX), did not alter the antiplatelet effects of low-dose aspirin in healthy volunteers.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples